Watch on LabRoots at labroots.com/webcast/id/816
Adjunct Professor of Psychiatry, University of California, San Diego, Honorary Visiting Senior Fellow, University of Cambridge, UK, Chairman, Neuroscience Education Institute (NEI), Editor-in Chief, CNS Spectrums, Director of Psychopharmacology Services, California Department of State Hospitals
Innovation in Psychopharmacology is Dead. Long Live Innovation in Psychopharmacology!
What’s going on in our field?
Priorities of Big Pharma shifting away from CNS and especially from psychiatry
Failed clinical trials littering the landscape
Even known drugs don’t work in psychiatric trials
Broken clinical trial apparatus
Iterative step-wise improvements or ‘me-too’ agents not reimbursed
Aggressive cost controls
No new validated targets
Learning objectives -
Discuss the reasons for the slow down of innovative new treatments entering psychopharmacology and the exit of Big Pharma largely from psychiatry
Show that future advances may be based on targeting symptoms that cut across a large array of psychiatric disorders
Propose that effective new treatments will be based upon subpopulations defined mostly in the short run by symptoms but in the long run by genetic and imaging biomarkers
22 июл 2024
